Drugs / AT03
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05201911 | Nov 2021 → Sep 2022 | amyloidosis | Attralus, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00788229 | Nov 2008 → Aug 2009 | dry eye syndrome | Dhp Korea Co., Ltd. | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-01-15 | Axcynsis Therapeutics Pte Ltd | Axcynsis Therapeutics Receives FDA Clearance for IND Application of AT03-65, a Differentiated CLDN6-Targeting ADC, Powered by AxcynDOT™ Technology axcynsis.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AT03 | “radiolabeled AT-03, a fusion protein of serum amyloid P and a single chain Fc receptor” NCT05201911 ↗ |
| Modality | Protein / enzyme biologic | “a fusion protein of serum amyloid P and a single chain Fc receptor” NCT05201911 ↗ |
| Route | Other | “eye drop for 12 weeks” NCT00788229 ↗ |